GLP-1 Agonists Lead the Global Race to Treat Fatty Liver Disease

Non-alcoholic fatty liver disease (NAFLD) affects roughly one quarter of the global population, yet no universally approved first-line pharmacotherapy exists. Lifestyle modification remains standard of care, making the rapid expansion of the NAFLD clinical trial landscape both urgently needed and scientifically significant. This study provides the most comprehensive mapping to date of global NAFLD trial activity and spotlights emerging therapeutic opportunities.

Researchers mined the Trialtrove database using the search terms NAFLD, MAFLD, and MASLD, ultimately identifying 2,242 clinical trials active through May 2025. Data captured included trial phase, status, sponsor type, drug names, molecular targets, and mechanisms of action. Complementary analyses included molecular docking of semaglutide against the GLP-1R protein structure and transcriptomic profiling of GLP-1R expression using public datasets (GSE61260, GSE89632, and E-MEXP-3291).

The geographic distribution of trials is highly uneven: the US leads with 488 trials, followed by China with 384, while all other nations fall below 300. Africa, West Asia, and Southeast Asia collectively account for a negligible share of global trial activity. Phase IV trials represent the largest proportion of all trials at 34.1%, followed by Phase II (25.0%), Phase I (23.9%), and Phase III (10.9%). Streamplot visualization of 1998–2024 data reveals rapid overall growth in trial launches, with Phase IV proportionally expanding in recent years while Phase I shows a slight contraction. Academic institutions sponsor the largest share of trials, ahead of industry and government.

Among all drug categories, natural products appeared in the most trials (294), but after excluding agents with unidentified pharmacological activity, GLP-1R agonists ranked first with 183 trials. GLP-1R itself was the top molecular target, followed by PPARγ, NR1H4 (FXR), SLC5A2 (SGLT-2), and PPARα. Semaglutide was the single most used agent across GLP-1RA trials, with liraglutide second. Molecular docking demonstrated semaglutide binds GLP-1R at an affinity score of −18.5 kcal/mol, with key hydrophobic interactions identified at multiple amino acid residues. Critically, transcriptomic data from three independent NAFLD datasets consistently showed significant downregulation of GLP-1R mRNA in NAFLD liver tissue, most pronounced in advanced NASH — reinforcing the mechanistic rationale for GLP-1RA intervention.

The findings highlight both promise and unmet need. While liraglutide (LEAN trial: 39% vs. 9% NASH resolution) and semaglutide (NCT02970942: 59% vs. 17% NASH resolution) show compelling histological benefits, fibrosis regression effects remain modest, pointing to a clear need for rational combination therapies. Geographic inequities in trial distribution also demand attention to ensure globally representative data and equitable access to emerging treatments.